Breast fibromixoid sarcoma in a young adult male. Case-report

Author:

Rodrigo Ayala-YáñezORCID,Roberto Zomar Fuentes-AstudilloORCID,Milagros Pérez Quintanilla

Abstract

Breast cancer in male patients is a rare clinical entity, representing less than 1% of all cancer incidence in males. Breast cancer is highly associated to hyperestrogenism, obesity and alcohol intake, and it is a disease mostly considered in female patients, hence, the lack of suspicion and proper evaluation in male patients. It must be considered that these tumors may be malignant and require an adequate protocol to avoid establishing diagnosis in advanced stages. This is the case of a 19-year-old male in Mexico City, who was diagnosed with a fibromixoid sarcoma, based on mastography and ultrasound imaging, biopsy and immunohistochemical signature. Tumor was excised through radical left breast mastectomy with final histologic diagnosis being fibromixoid sarcoma (T2a N0 M0), clinical stage IB. No further treatment was required, and periodical outpatient consultations are performed for follow up. The most significant risk factor found in our patient was an increased body mass index (BMI), smoking and alcohol consumption.

Publisher

MedCrave Group Kft.

Subject

General Medicine

Reference17 articles.

1. Breast cancer in men;Giordano;N Engl J Med,2018

2. Incidence and outcome of male breast cancer: an international population-based study;Miao;J Clin Oncol,2011

3. Global Cancer Observatory, International Agency for Research on Cancer. World Health Organization. Breast. Globocan 2020.

4. Centers for Disease Control and Prevention. Male breast cancer incidence and mortality, United States-2013-2017. USCS Data Brief, no 19. Altanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2020.

5. Maretty-Nielsen K, Baerentzen S, Keller J, et al. Low-grade fibromyxoid sarcoma: incidence, treatment strategy of metastases, and clinical significance of the FUS gene. Sarcoma. 2013.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3